Form 4: Acrivon Therapeutics Executives Report Stock Transactions

Acrivon Therapeutics executives Peter Blume-Jensen and Kristina Masson reported transactions involving company common stock on May 14, 2026.

Summary

• Peter Blume-Jensen, President and CEO and Director, acquired 1,253 shares of common stock on May 14, 2026, for $1.92 per share, which were withheld by the Issuer to satisfy mandatory tax withholding requirements upon vesting of restricted stock units. Following this transaction, he beneficially owns 2,078,951 shares directly.
• Kristina Masson, EVP - Business Operations and Director, acquired 490 shares of common stock on May 14, 2026, for $1.92 per share, also withheld by the Issuer for tax purposes. Following this, she beneficially owns 313,637 shares indirectly.
• Both executives are spouses, and they have disclaimed beneficial ownership of securities held by the other, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The transactions are routine for executive compensation and tax management, with no indication of buying or selling based on company performance.

Positives

• Executives are retaining shares after tax withholding, indicating confidence in the company.
• The transactions are related to the vesting of restricted stock units, a common form of executive compensation.

Negatives

• The transactions represent shares withheld for tax purposes, not new purchases by executives.
• The filing does not provide details on the total value of the vested restricted stock units.

Risks

• The filing does not explicitly mention any risks.
• Potential for future stock sales by executives could impact share price, though not detailed here.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Management Comments

• Dr. Peter Blume-Jensen disclaims beneficial ownership of securities held by Dr. Kristina Masson except to the extent of his pecuniary interest therein.
• Dr. Kristina Masson disclaims beneficial ownership of securities held by Dr. Peter Blume-Jensen except to the extent of her pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The withholding of shares for tax purposes upon vesting of RSUs is a common practice and does not necessarily indicate a change in management's long-term view of the company's prospects.

Related Party Transactions

• Peter Blume-Jensen and Kristina Masson are spouses, and they have disclaimed beneficial ownership of each other's securities except to the extent of their pecuniary interest.

Stakeholder Impact

• Shareholders: No immediate impact, as these are routine tax-related withholdings. However, significant future insider selling could influence share price.
• Employees: The transactions relate to executive compensation, which is a standard component of employee incentives at this level.
• Management: The transactions reflect the standard compensation and tax management practices for senior leadership.

Next Steps

• Continued monitoring of insider transactions for any changes in beneficial ownership that might signal shifts in executive confidence.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Stock Transaction, Beneficial Ownership, Peter Blume-Jensen, Kristina Masson, Restricted Stock Units, Tax Withholding, Executive Compensation